ALTSTATION.IO

AstraZeneca PLC (AZN) Stock Analysis

By Nova Skye | AltStation.io | Updated February 07, 2026

Price

$192.82

Change

+3.02%

Market Cap

$298.93B

Avg Volume

216.2K

Company Overview

AstraZeneca PLC, based in Cambridge, United Kingdom, develops and markets prescription medicines across a range of therapeutic areas including oncology, cardiovascular, renal, and respiratory diseases. Their portfolio includes well-known drugs such as Tagrisso for lung cancer, Farxiga for diabetes and heart failure, and Imfinzi for cancer treatment. AstraZeneca sells its products primarily to healthcare providers, including both primary and specialty care physicians, through various distribution channels worldwide.

In the competitive landscape, AstraZeneca is considered a market leader, especially in oncology, where it ranks among the top biopharmaceutical companies globally. Its robust pipeline, extensive collaborations, and a strong focus on innovation set it apart from key competitors like Pfizer and Bristol Myers Squibb. However, challenges such as patent expirations and aggressive pricing pressures could threaten its market position, particularly as biosimilars and generics gain traction.

Currently, AstraZeneca is in a growth phase, bolstered by strong demand for its oncology products and a healthy development pipeline. Recent milestones include strategic partnerships for drug development and progress in their collaborations to enhance computational chemistry for breakthrough therapies. The success of new launches, like the asthma medication Tezspire, indicates that AstraZeneca is effectively pivoting towards next-generation therapies while maintaining a strong foothold in its core markets.

Key Financials

Market Cap

$298.93B

Revenue

$58.13B

EBITDA

$20.42B

Gross Margin

83.3%

Profit Margin

16.2%

Revenue Growth

12.0%

Total Cash

$8.18B

Total Debt

$32.66B

Free Cash Flow

$9.98B

52-Week Price Performance Analysis

Price Statistics

P/E Ratio

64.06

Forward P/E

38.11

Beta

0.19

52-Week High

$195.00

52-Week Low

$93.03

EPS

$3.01

50-Day Avg

$183.95

200-Day Avg

$160.50

Price/Book

6.52

Technical Analysis

AstraZeneca PLC (AZN) has exhibited a strong bullish trend over the past 52 weeks, increasing from approximately $145 in mid-2022 to the current price of $192.82, representing a 32.2% gain. Key support is observed around $140, with a significant resistance level near $193.03; this serves as a psychological barrier as it approaches its 52-week high. A notable ascending triangle pattern appears to have formed, suggesting potential for continued upward momentum as the stock nears resistance. In recent weeks, AZN has maintained a steady upward trajectory, with prices consistently above the 200-day moving average, indicating sustained bullish sentiment. Currently, the stock is trading just below its 52-week high, implying strong market confidence and the possibility of breaking through this resistance if buying pressure continues. This position suggests that investors may remain optimistic about short-term gains, although caution should always be exercised near resistance levels.

Recent News and Developments

Market Update

Here’s a summary of the latest news and developments for AstraZeneca PLC (AZN) stock in the past week, covering February 1 to February 7, 2026:

1. Upcoming Full-Year 2025 Earnings Report Anticipated

AstraZeneca is scheduled to release its full-year 2025 financial results on February 10, 2026. Analysts are expecting the company to report earnings of $2.18 per share, which would represent a significant year-over-year growth of 107.62%. Revenue for the quarter is projected to be $15.71 billion, an increase of 5.48% compared to the same period last year.

2. U.S. Stock Listing Transitioned to NYSE

Effective Monday, February 2, 2026, AstraZeneca completed its transition of U.S. listing from Nasdaq to the New York Stock Exchange (NYSE). This move involved delisting its American Depositary Shares (ADS) from Nasdaq and directly listing its ordinary shares, aiming to simplify its structure and allow global investors to trade consistently without ADS intermediaries.

Market Sentiment and Analyst Recommendations

Bull Case

AstraZeneca’s 12% revenue growth combined with expected earnings growth of 107.62% in 2025 shows the company is actually executing, not just talking about it. The $15 billion China investment signals aggressive expansion in high-growth markets, particularly in cell therapy where Gracell gives them existing infrastructure. DATROWAY’s Priority Review decision coming in Q2 2026 could unlock significant revenue in triple-negative breast cancer, a market with limited first-line options. The NYSE transition removes friction for institutional investors and simplifies trading mechanics globally. The stock has climbed 32.2% over 52 weeks and sits near all-time highs, but that’s because the fundamentals are strengthening, not weakening. Pipeline depth across oncology and specialty care gives multiple shots at approval wins over the next 12 months.

Bear Case

The P/E of 64.06 is stretched for a company trading near its 52-week high with only 12% revenue growth. Debt stands at $32.66 billion against cash of $8.18 billion, leaving net debt of $24.48 billion — that’s a real burden if growth slows or interest rates stay elevated. Analyst consensus price target of $104.50 sits 46% below current price, which is a massive red flag most investors are ignoring. The Saphnelo SC setback shows pipeline execution isn’t flawless, and regulatory surprises will happen. Trading at psychological resistance near $193 with limited room to run higher makes risk-reward unfavorable here. Valuation assumes everything goes right; one major disappointment could trigger a sharp correction back toward $140 support.

What to Watch

February 10 earnings report is the immediate test — watch for any guidance cuts or pipeline delays that would validate the bear case on valuation. DATROWAY’s FDA decision in Q2 2026 is binary and could move the stock 5-10% either direction depending on label breadth and competitive positioning. Monitor debt reduction progress; if net debt stays elevated above $24 billion while growth moderates, multiple compression becomes inevitable. Saphnelo SC resubmission timing and any FDA feedback in H1 2026 matters for the lupus franchise trajectory. Track quarterly revenue growth rates closely — if that 12% figure starts decelerating toward single digits, the P/E multiple has no support. Watch whether the China investment begins showing tangible returns by late 2026; capital deployment credibility is on the line.

Analyst Consensus

BUY

Based on 2 analyst opinions

Low Target

$104.00

Mean Target

$104.50

High Target

$105.00

Earnings and Financial Data

Sector

Healthcare

Industry

Drug Manufacturers – General

Employees

94,300

Earnings & Dividends

Next Earnings

Feb 10, 2026

EPS (Trailing)

$3.01

Dividend Yield

169.0%

Payout Ratio

52.0%

Frequently Asked Questions

Is AZN a good stock to buy?

Analysts recommend a BUY rating for AstraZeneca (AZN) with a target price of $104.50. Given its current price of $192.82, this suggests potential downside rather than upside in the near term.

What is AZN’s price target?

The price target for AstraZeneca is set at $104.50. This is significantly lower than the current trading price of $192.82, indicating a cautious outlook from analysts.

Does AZN pay a dividend?

AstraZeneca has a high dividend yield of 169.0%. This impressive yield may attract income-focused investors, but it’s essential to confirm the sustainability of this distribution.

What are AZN’s earnings metrics?

AstraZeneca has a price-to-earnings (P/E) ratio of 64.06 and a forward P/E of 38.11. These numbers suggest the stock may be overvalued compared to its earnings potential.

What is AZN’s market capitalization?

AstraZeneca’s market capitalization stands at $298.93 billion. This positions the company as one of the significant players in the healthcare sector, especially in drug manufacturing.

Related Stock Reports

Disclaimer: This report is for informational purposes only and does not constitute financial advice. The analysis and opinions expressed are those of AltStation.io and should not be relied upon as the sole basis for investment decisions. Always conduct your own research and consult with a qualified financial advisor before making investment decisions. Past performance does not guarantee future results. Updated February 07, 2026.